Hepatitis B surface antigen seroconversion is associated with favourable long‐term clinical outcomes during lamivudine treatment in HBeAg‐negative chronic hepatitis B patients
暂无分享,去创建一个
R. Idilman | C. Yurdaydın | K. Çınar | G. Seven | Y. Bozkuş | A. Elhan | M. Bozdayi | K. Bahar | K. Bahar | M. Bozdayı | K. Cinar | Kubilay Cinar
[1] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[2] C. Chu,et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study , 1991, Hepatology.
[3] E. Schiff,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.
[4] Ally,et al. A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .
[5] H. Kumada,et al. [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.
[6] M. Yuen,et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.
[7] B. McMahon,et al. Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus , 2001, Annals of Internal Medicine.
[8] J. George,et al. Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance , 2002, American Journal of Gastroenterology.
[9] M. Colombo,et al. Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy , 2003, Hepatology.
[10] Ching-Lung Lai,et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.
[11] Ching-Lung Lai,et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] C. Yurdaydın,et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients , 2004, Archives of Virology.
[13] C. Gibbs,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.
[14] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[15] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[16] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[17] V. Wong,et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. , 2005, Gastroenterology.
[18] N. Leung,et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.
[19] K. Tanikawa,et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.
[20] H. Janssen,et al. Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype , 2006, The American Journal of Gastroenterology.
[21] Guan-Tarn Huang,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.
[22] Chien-Jen Chen,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.
[23] Olga Angelopoulou,et al. Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels , 2007, Antiviral therapy.
[24] M. Yuen,et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5‐year ideal response , 2007, Hepatology.
[25] B. Jang,et al. Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus. , 2007, Gut and liver.
[26] V. Wong,et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] M. Yuen,et al. The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points , 2007, Annals of Internal Medicine.
[28] Jörg Petersen,et al. EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.
[29] E. Steyerberg,et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.
[30] F. Zoulim,et al. Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.
[31] R. Idilman,et al. A short course of add‐on adefovir dipivoxil treatment in lamivudine‐resistant chronic hepatitis B patients , 2009, Journal of viral hepatitis.
[32] P. André,et al. Clearance of serum HBsAg and anti‐HBs seroconversion following antiviral therapy for chronic hepatitis B , 2009, Journal of medical virology.
[33] P. Marcellin,et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.
[34] P. Marcellin,et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.
[35] V. Wong,et al. Surrogate end points and long-term outcome in patients with chronic hepatitis B. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[36] Y. Liaw. Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[37] S. Lewin,et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers , 2010, Hepatology.
[38] C. Boucher,et al. Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.
[39] R. D. de Man,et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B * , 2010, Journal of viral hepatitis.
[40] Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series. , 2010, European review for medical and pharmacological sciences.
[41] Heon-Ju Lee,et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. , 2010, Journal of hepatology.
[42] C. Boucher,et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. , 2011, Journal of hepatology.
[43] R. Thimme,et al. Natural history of chronic hepatitis B virus infection , 2014, Medical Microbiology and Immunology.